Literature DB >> 1484939

A clinical study of type 2 neurofibromatosis.

D G Evans1, S M Huson, D Donnai, W Neary, V Blair, V Newton, R Harris.   

Abstract

The clinical features, age at onset of symptoms and survival of 150 patients with type 2 neurofibromatosis were studied. The mean age at onset was 21.57 years (n = 110) and no patients presented after 55 years of age. Patients presented with symptoms attributable to vestibular schwannomas (acoustic neuroma), cranial meningiomas and spinal tumours. In 100 patients studied personally by the authors 44 per cent presented with deafness and this was unilateral in the majority (35/44). Deafness was accompanied by tinnitus in a further 10 per cent and muscle weakness or wasting was the first symptom in 12 per cent. Less common presenting symptoms were seizures (8 per cent), vertigo (8 per cent) numbness and tingling (2 per cent) and blindness (1 per cent). Eleven patients were diagnosed asymptomatically through screening. Café au lait spots occurred in 43 per cent (n = 43) but only one case had six. Skin tumours were detected in 68 per cent (68/100) and 38 per cent (34/90) had an identifiable lens opacity or cataract. The mean age at death in 40 cases was 36.25 years and all but one death was a result of a complication of neurofibromatosis. There are marked inter-family differences in disease severity and tumour susceptibility.

Entities:  

Mesh:

Year:  1992        PMID: 1484939

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  147 in total

Review 1.  Neurology and the skin.

Authors:  O Hurko; T T Provost
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-04       Impact factor: 10.154

Review 2.  Paternal factors and schizophrenia risk: de novo mutations and imprinting.

Authors:  D Malaspina
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

Review 3.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

4.  Type II neurofibromatosis presenting as quadriceps atrophy.

Authors:  L Grazzi; L Chiapparini; E A Parati; S Giombini; D D'Amico; M Leone; G Bussone
Journal:  Ital J Neurol Sci       Date:  1998-04

5.  Hereditary spinal neurofibromatosis: a rare form of NF1?

Authors:  M Poyhonen; E L Leisti; S Kytölä; J Leisti
Journal:  J Med Genet       Date:  1997-03       Impact factor: 6.318

6.  Uptake of genetic testing for cancer predisposition.

Authors:  D G Evans; E R Maher; R Macleod; D R Davies; D Craufurd
Journal:  J Med Genet       Date:  1997-09       Impact factor: 6.318

7.  Predictors of the risk of mortality in neurofibromatosis 2.

Authors:  Michael E Baser; J M Friedman; Dana Aeschliman; Harry Joe; Andrew J Wallace; Richard T Ramsden; D Gareth R Evans
Journal:  Am J Hum Genet       Date:  2002-08-22       Impact factor: 11.025

8.  Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.

Authors:  Kiran K Mantripragada; Patrick G Buckley; Caroline Jarbo; Uwe Menzel; Jan P Dumanski
Journal:  J Mol Med (Berl)       Date:  2003-06-27       Impact factor: 4.599

9.  A 163-bp deletion in the neurofibromatosis 2 (NF2) gene associated with variant phenotypes [corrected].

Authors:  L Kluwe; S M Pulst; J Köppen; V F Mautner
Journal:  Hum Genet       Date:  1995-04       Impact factor: 4.132

10.  Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms.

Authors:  D G R Evans; E R Maher; M E Baser
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.